autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes

Cell therapyexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started May 20, 2015 (NCT02408016)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02770820Phase 1/Phase 2 (Phase 2)Jan 1, 2018National Cancer Institute (NCI), University of Washington
NCT02408016Phase 1/Phase 2 (Phase 2)May 20, 2015National Cancer Institute (NCI), University of Washington
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government2012015
University of WashingtonAcademic/Hospital2212015
2 organizations
Page 1 / 1